ImpediMed Ltd Investor Conference Call Transcript
Thank you for standing by, and welcome to the ImpediMed Limited PREVENT Trial Results Investor Conference Call. (Operator Instructions) I would now like to hand the conference over to Mr. Richard Carreon, Managing Director and CEO. Please go ahead.
Thanks, Kaley. Welcome, everyone, and thank you for joining us today. We're hosting this call to discuss the results of the PREVENT trial, which were just released to the ASX.
On the call today joining me is Tim Cruickshank, our Chief Financial Officer; and Mike Bassett, our Senior Vice President of Corporate and Strategic Development. At the conclusion of our remarks, we'll be taking questions.
First of all, we are very, very pleased to announce the PREVENT trial successfully met its primary endpoint and reached statistical significance. Now as background, the PREVENT trial is a pivotal study. It's the single largest study ever undertaken in lymphedema, and the PREVENT study is a level I randomized controlled trial to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
